Company Overview
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Recent Developments
- Dec 2025 Revenue of $11.51M (-1.5% YoY); net profit $-53.58M.
- Trailing 12 Months Year-on-year growth — revenue -58.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.17% |
| 1 Year: | -58.90% |
Stock Price Performance
| 1 Year: | -99.54% |
| 6 Months: | -97.59% |
| 3 Months: | -84.83% |
| 1 Month: | -56.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)19.32 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 19 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JAGX Jaguar Health, Inc. PHARMA | 0.41 | 0.00 | $177.99K | 0.00% | - | - | 4.17% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 896.52K | - | - | 883.85K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.95M | -1.94M | -2.58M | -2.68M | -3.17M | -2.75M | -3.68M | -3.41M | -3.18M | -3.88M | -2.35M | -7.34M | -5.13M | -7.08M | -6.51M | -5.78M | -10.62M | -6.73M | -7.65M | -8.45M | -5.38M | -8.77M | -11.58M | -9.53M | -11.75M | -6.48M | -9.90M | -9.85M | -8.10M | -8.79M | -8.21M | -7.20M | -7.26M | -9.42M | -8.01M | -7.24M | 10.18M |
| Net Income | -1.97M | -1.94M | -2.73M | -3.94M | -5.26M | -2.96M | -3.98M | -3.66M | -3.42M | -4.72M | -1.81M | 4.76M | -5.70M | -7.66M | -6.14M | -8.30M | -16.72M | -7.55M | -7.94M | -9.24M | -7.87M | -12.01M | -14.08M | -12.19M | -17.99M | -9.37M | -12.52M | -12.20M | -12.15M | -7.78M | -9.23M | -9.49M | -9.85M | -10.46M | -10.41M | -9.50M | - |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.30 | - | - | 1.11 | - | - | -0.51 | - | - | - | - | -0.44 | -0.62 | -0.28 | -0.31 | -0.27 | -23.10 | -8.77 | -8.83 | -2.39 | -41.35 | -22.50 | -87.12 | -2.66 | -26.29 | -584.45 | -10.26 | -6.28 | -13.60 |
| R&D Expense | 1.46M | 691.18K | 1.13M | 1.42M | 1.75M | 1.24M | 1.75M | 1.95M | 1.97M | 1.26M | 926.79K | 851.61K | 757.87K | 1.60M | 1.48M | 1.42M | 1.70M | 1.31M | 1.58M | 1.41M | 1.52M | 2.41M | 3.87M | 3.31M | 4.95M | 2.45M | 5.94M | 4.78M | 4.28M | 6.08M | 4.31M | 3.65M | 4.04M | 3.73M | 3.27M | 3.66M | 3.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 258.38K | 141.52K | 4.36M | 4.42M | 5.78M | 9.38M | 4.33M | 11.96M | 9.76M | 11.69M | 11.51M |
| Operating Income | -8.32M | -12.45M | -13.59M | -34.25M | -30.82M | -28.95M | -26.65M | -40.71M | -34.41M | -34.29M | -30.83M | -45.91M |
| Net Income | -8.61M | -16.29M | -14.73M | -21.97M | -32.15M | -38.54M | -33.81M | -52.59M | -47.45M | -41.30M | -38.49M | -53.58M |
| Diluted EPS | - | - | - | - | - | - | -3.00 | -88.22 | -36.18 | -2,678.17 | -130.69 | -22.97 |
| R&D Expense | 4.22M | 6.48M | 7.21M | 4.27M | 5.15M | 5.82M | 6.41M | 15.08M | 17.65M | 18.60M | 16.54M | 24.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.42M | 12.41M | 3.56M | 43.63M | 41.04M | 36.41M | 42.84M | 53.27M | 47.45M | 50.76M | 53.42M | 38.32M |
| Total Equity | -434.85K | -8.24M | 4.40M | -2.45M | 17.26M | 5.38M | 10.67M | 17.20M | 11.85M | -1.36M | 4.90M | 6.49M | -18.69M |
| Cash & Equivalents | 185.37K | 845.19K | 7.70M | 950.98K | 520.70K | 2.57M | 3.50M | 8.09M | 17.05M | 5.47M | 6.47M | 8.00M | 968.00K |
| Long Term Debt | - | - | 4.10M | 1.82M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 5.35M | 8.01M | 6.02M | 26.37M | 26.66M | 15.84M | 25.64M | 41.41M | 48.81M | 45.87M | 44.45M | 57.01M |
| Current Liabilities | - | 3.48M | 3.91M | 4.19M | 15.39M | 26.66M | 15.39M | 13.22M | 15.47M | 30.34M | 13.99M | 19.70M | 40.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -14.41M | -9.82M | -22.73M | -20.46M | -15.28M | -34.97M | -33.10M | -33.24M | -29.38M | -23.69M |
| Investing Cash Flow | - | - | 2.38M | -1.56M | -6.53K | - | -7.00K | -6.00K | -1.68M | - | -231.00K | -41.00K |
| Financing Cash Flow | - | - | 5.28M | 10.68M | 24.55M | 21.77M | 19.49M | 43.94M | 23.18M | 34.23M | 31.20M | 23.67M |
| Capital Expenditure | -55.15K | -23.30K | -104.21K | - | -6.53K | - | -7.00K | -6.00K | -77.00K | - | -16.00K | - |
| Free Cash Flow | - | - | -14.52M | - | -22.74M | - | -15.29M | -34.98M | -33.18M | - | -29.40M | - |
| Share Buybacks | - | - | - | - | 30 | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -4,816.7% | -9,599.8% | -785.3% | -698.0% | -501.3% | -283.9% | -939.1% | -287.8% | -351.3% | -263.8% | -398.8% |
| Net Margin % | - | -6,305.2% | -10,410.9% | -503.7% | -727.9% | -667.3% | -360.2% | -1,213.3% | -396.9% | -423.1% | -329.3% | -465.4% |
| ROE % | 104.5% | -370.3% | 600.4% | -127.3% | -597.2% | -361.1% | -196.5% | -443.7% | 3,491.8% | -843.4% | -592.7% | 286.7% |
| ROCE % | -880.3% | -146.5% | 2,157.5% | -121.3% | -214.3% | -137.7% | -90.0% | -107.7% | -201.1% | -93.2% | -91.4% | 1,969.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | - | 267 | $723 |
| 2 | Tower Research Capital LLC (TRC) | - | 77 | $208 |
| 3 | SBI Securities Co., Ltd. | - | 6 | $16 |
| 4 | Barclays Plc | - | 4 | $10 |
| 5 | Royal Bank of Canada | - | 1 | $2 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JAGX
Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise
The non-prescription digestive-support product extends Jaguar Health’s Neonorm franchise into the companion-animal market, with additional online and retail distribution expected shortly. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) ha…
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogsJaguar expects Neon…
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric rare IF diseases, including microvillus inclusion disease (MVID) and short bowel syndr…
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs. The Neonorm franchise currently includes Neonorm Foal and Neono…
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ...
Jaguar Health Inc (JAGX) reports groundbreaking MVID trial results and secures $18M in non-dilutive capital via FuturePak deal, despite a 60% revenue decline.
Jaguar Health Reports Second Quarter 2026 Financials
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crof…
JAGX — Frequently Asked Questions
What is the current share price of Jaguar Health, Inc. (JAGX)?
As of 2026-09-19 21:16 PDT, Jaguar Health, Inc. (JAGX) trades at $0.41 on NasdaqCM. Its 52-week range is $0.41 to $90.65.
What is the market capitalisation of JAGX?
Jaguar Health, Inc. (JAGX) has a market capitalisation of $177.99K on NasdaqCM.
Is JAGX a good stock to buy?
This page provides a data-driven analysis of Jaguar Health, Inc. (JAGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.